{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-048364","form_type":"8-K","ticker":"ORKA","cik":"0000907654","company_name":"Oruka Therapeutics, Inc.","filed_at":"2024-04-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.396897+00:00","generated_at":"2026-06-03T09:00:57.948391+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ARCA biopharma Q1 net loss $2.0M, cash $35.9M; Oruka merger and CEO change detailed","bullets":["Net loss for Q1 2024 was $2.0M ($0.14 per share) vs $1.3M ($0.09) in Q1 2023.","Cash and equivalents $35.9M at March 31, 2024, down from $37.4M at Dec. 31, 2023; funds operations through mid-2025.","G&A expenses rose to $2.3M from $1.4M due to $1.1M in professional fees related to the Oruka merger.","CEO Michael Bristow separated effective April 3, 2024; Thomas Keuer appointed President and principal executive officer.","Merger with Oruka Therapeutics is subject to conditions; failure could lead to dissolution or alternative strategic transaction."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-048364","json":"https://secwatch.observer/filing/0000950170-24-048364.json","markdown":"https://secwatch.observer/filing/0000950170-24-048364.md","text":"https://secwatch.observer/filing/0000950170-24-048364.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/907654/000095017024048364/0000950170-24-048364-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/907654/000095017024048364/abio-20240425.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T09:00:57.948391+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d0f8677ec81147100c8b318eb312b3a8173bd520","claim":"Oruka Therapeutics, Inc. reported financial results for first quarter 2024.","evidence_excerpt":"ARCA biopharma, Inc. (Nasdaq: ABIO), (the “Company”) a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported first quarter 2024 financial results and provided a corporate update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/907654/000095017024048364/0000950170-24-048364-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}